GENELUX Corp (GNLX)

↓ Download CSV

CIK 0001231457 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, GENELUX Corp reported revenue of $8.0K, up 0.0% from the prior year. The company ran a net loss, with a net margin of -401812.5%. It held $19.03M in total assets against $7.48M in total liabilities.

Key ratios (FY2025)

-415175.0%
Operating margin
-401812.5%
Net margin
-278.5%
Return on equity
+0.0%
Revenue growth (YoY)
Metric (FY)20252024202320222021
Revenue$8.0K$8.0K$170.0K$11.07M
Operating Income-$33.21M-$31.70M-$24.16M-$3.01M
Net Income-$32.15M-$29.87M-$28.30M-$5.21M
EPS (Diluted)$-0.86$-0.95$-1.16$-0.57
Total Assets$19.03M$34.72M$27.89M$5.53M
Total Liabilities$7.48M$8.44M$8.42M$41.31M
Shareholders' Equity$11.54M$26.27M$19.47M-$35.78M-$33.11M
Cash & Equivalents$5.33M$8.56M$9.42M$397.0K
Operating Cash Flow-$25.27M-$21.23M-$20.27M-$3.57M
Capital Expenditures$1.10M$381.0K$1.02M$49.0K
Shares Outstanding38.14M34.73M26.79M9.13M